Funded Tech Companies

bluebird bio

Wondering who provided funding to bluebird bio? Shire Pharmaceuticals, Deerfield Capital and private investors invested in this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

6/19/2013

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Nick Leschly

        

Chief Financial Officer

Jeffrey Walsh

        

Chief Medical Officer

David Davidson

        

Chief Scientific Officer

Philip Gregory

        

Chief Technical Officer

Derek Adams

        

VP - Bus. Development

Joanne Smith-Farrell

        

VP - General Counsel

Jason Cole

        

VP - Human Resources

Kathy Wilkinson

        

Company Investors

• Shire Pharmaceuticals
• Deerfield Capital (Howard Furst)
• RA Capital
• Third Rock Ventures (Robert Tepper)
• Forbion Capital Partners (Geert-Jan Mulder)
• Arch Venture Partners (Steven Gillis)
• Easton Capital
• TVM Capital (Axel Polack)
• Genzyme Ventures (James Geraghty)
• Third Rock Ventures (Nick Leschly)
• Forbion Capital Partners (Geert Mulder)
• Johnson & Johnson Development Corporation
• Nazem & Co.
• Easton Capital (John Friedman)
• TVM Capital (Stephen Hoffman)

Browse more funded tech companies:

Blueberry Home | Bluebirds

Share this article

About Our VC Deals Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary